David Gray
Company: Vigil Neuroscience
Job title: Chief Scientific Officer
Seminars:
Panel Discussion: Untangling the Future of Neuroimmunology Drug Development in the Wake of TREM2 Trial Results: To What Extent are Current TREM2 Models Fit For Purpose? 4:30 pm
Exploring how clinical validation of TREM2 will inform back translation and to what extent our current models still fit for purpose Navigating trial impact on preclinical model validation to better recapitulate neuroinflammatory pathology Evaluating the probable impact of inhibiting or stimulating microglia to reduce pathological neuroinflammation? How can we build on the next generation of…Read more
day: Conference Day One
Modulating TREM2 with Multiple Modalities to Treat Rare Genetically Defined Microgliopathies (VGL101) & Alzheimer’s Disease (VG-3927) 3:00 pm
Navigating VG-3927 small molecule approach to TREM2 agonism to address unmet needs in Alzheimer’s Disease Exploring phase 2 results of targeting rare genetically defined microgliopathies with Iluzanebart (VGL101) for ALSP2 by increasing signaling through DAP12/SYK to mitigate microglial dysfunction downstream Navigating genetic and biomarker strategies to aid early development and how a small molecule TREM2…Read more
day: Conference Day One